Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2

Blocking IL-6 pathways with sarilumab, a fully human anti–IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used “off-label” sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Corominas, Hèctor, Castellví, Ivan, Diaz-Torné, César, Matas, Laia, de la Rosa, David, Mangues, Maria Antònia, Moya, Patricia, Pomar, Virginia, Benito, Natividad, Moga, Ester, Sosa, Nerea Hernandez-de, Casademont, Jordi, Domingo, Pere
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
3600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133253/
https://www.ncbi.nlm.nih.gov/pubmed/34106658
http://dx.doi.org/10.1097/MD.0000000000025923
Descripción
Sumario:Blocking IL-6 pathways with sarilumab, a fully human anti–IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used “off-label” sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.

Ejemplares similares